Clinical Studies of Vaccine Against Smallpox on the Base of Recombinant <i>Vaccinia</i> b7,5S2-S Strain under the Conditions of Double Oral Vaccination

Abstract

Volunteers who had been vaccinated against smallpox in their childhood were orally immunized with Revax-BT vaccine - initially with a small dose, then (in 7, 14, 30, 90 and 180 days) with a large one. Slight reactogenicity was observed after the first vaccination whereas revaccination induced no clinical manifestation. Double immunization with this preparation with 1-2 weeks interval proved to be the most effective method: the protective level of virus-neutralizing antibodies to vaccinia virus (VV) was formed in 90-100 % volunteers in a month after vaccination, and 6 months later this index decreased up to 70 %. The recombinant VV was not registered in the samples of blood, saliva and urine taken from the volunteers after double immunization.

Keywords

• recombinant virus of vaccinia
• smallpox
• hepatitis b
• tablet vaccine
• oral use
• clinical trial
• double vaccination
• cellular immunity
• humoral immunity
• reactogenicity
• safety